How to Get Vanflyta (Quizartinib) Covered by Cigna in Washington: Complete Prior Authorization & Appeals Guide
Answer Box: Getting Vanflyta (Quizartinib) Covered by Cigna in Washington
Cigna requires prior authorization for Vanflyta (quizartinib) in FLT3-ITD-positive AML patients ≥18 years old with confirmed mutation via FDA-approved testing. Submit comprehensive documentation including baseline ECG showing QTc <450ms, REMS enrollment proof, and oncologist's medical necessity letter. If denied, Washington residents have strong appeal rights including external review by an Independent Review Organization (IRO) within 180 days. First step today: Contact your oncologist to gather FLT3-ITD test results and baseline cardiac monitoring before submitting your PA request through CoverMyMeds or Cigna's provider portal.
Table of Contents
- Understanding Cigna's Vanflyta Coverage Requirements
- Step-by-Step: Fastest Path to Approval
- Common Denial Reasons & How to Fix Them
- Medical Necessity Letter Requirements
- Washington Appeals Process: Your Rights
- External Review Through Washington's IRO System
- Cost Considerations & Financial Assistance
- When to Contact Washington Regulators
- Frequently Asked Questions
Understanding Cigna's Vanflyta Coverage Requirements
Vanflyta (quizartinib) is a specialized FLT3 inhibitor for acute myeloid leukemia that costs approximately $16,100-$17,900 per 28-day supply. Cigna requires prior authorization for all Vanflyta prescriptions, approving coverage for one year when specific clinical criteria are met.
Coverage at a Glance
| Requirement | What It Means | Where to Find It |
|---|---|---|
| Age ≥18 years | Patient must be adult | Birth certificate/medical records |
| FLT3-ITD positive AML | Confirmed mutation via FDA-approved test | CLIA-certified lab report |
| Baseline ECG | QTc <450ms required | Cardiology or oncology clinic |
| REMS enrollment | Safety program participation | VANFLYTA REMS website |
| Oncologist prescription | Hematology/oncology specialist | Provider credentials verification |
The approval covers both combination therapy during induction/consolidation phases and single-agent maintenance therapy following consolidation treatment.
Step-by-Step: Fastest Path to Approval
1. Confirm Your Diagnosis Documentation
Who does it: Your oncologist's office
What's needed: Bone marrow biopsy report confirming AML diagnosis with FLT3-ITD mutation via FDA-approved testing
Timeline: Gather within 1-2 business days
Submit via: Include in PA packet
2. Complete Cardiac Safety Requirements
Who does it: Cardiology or oncology clinic
What's needed: Baseline ECG showing QTc <450ms within 30 days of treatment start
Timeline: Same-day or next-day appointment
Why it matters: Vanflyta prolongs QT interval and requires cardiac monitoring
3. Enroll in REMS Program
Who does it: Patient and prescriber together
What's needed: Complete enrollment at VANFLYTA REMS
Timeline: 24-48 hours for processing
Submit via: Include enrollment confirmation in PA request
4. Submit Comprehensive PA Request
Who does it: Oncologist's office
What's needed: Complete medical necessity letter with all supporting documents
Timeline: 5-7 business days for standard review; 24-72 hours for expedited
Submit via: CoverMyMeds or Cigna provider portal
5. Track Your Request
Who does it: Patient or clinic staff
What's needed: PA confirmation number
Timeline: Check status after 3-5 business days
Contact: Cigna Provider Services at 1-800-882-4462
Common Denial Reasons & How to Fix Them
| Denial Reason | How to Overturn |
|---|---|
| Missing FLT3-ITD documentation | Submit FDA-approved test from CLIA-certified lab with mutation details |
| Incomplete cardiac monitoring | Provide baseline ECG with QTc measurement and interpretation |
| REMS enrollment not verified | Include REMS confirmation letter or enrollment screenshot |
| Non-FDA approved testing method | Retest using FDA-approved FLT3-ITD assay; submit new lab report |
| Missing treatment history | Document prior therapies, responses, and reasons for Vanflyta selection |
Tip: Over 90% of initial PA requests are approved when all required documentation is included in the first submission.
Medical Necessity Letter Requirements
Your oncologist's medical necessity letter should address these key elements:
Patient Information Section:
- Full name, date of birth, Cigna member ID
- Primary diagnosis with ICD-10 code (C92.0 for AML)
- FLT3-ITD mutation status and test details
Clinical Rationale:
- Detailed treatment history and prior therapy outcomes
- Explanation of why Vanflyta is medically necessary
- Reference to FDA labeling for FLT3-ITD-positive AML
- NCCN Guidelines support for treatment approach
Monitoring Plan:
- Cardiac monitoring protocol per FDA requirements
- Laboratory monitoring schedule
- Treatment duration and goals
Supporting Evidence:
- Peer-reviewed literature supporting Vanflyta use
- Professional guidelines (NCCN, ELN) citations
- Clinical trial data if applicable
Counterforce Health specializes in helping patients navigate complex prior authorization requirements by creating evidence-backed appeals that address payer-specific criteria. Their platform analyzes denial letters and drafts targeted rebuttals using the right clinical evidence and procedural requirements for each insurance plan.
Washington Appeals Process: Your Rights
Washington State provides robust protection for patients facing insurance denials. If Cigna denies your Vanflyta request, you have multiple levels of appeal available.
Internal Appeal Timeline
- Filing deadline: 180 calendar days from denial notice
- Processing time: 60 days for standard review
- Expedited option: Available if delay could seriously jeopardize your health
- Required forms: Cigna medical appeal form (available through member portal)
What to Include in Your Appeal
- Original denial letter
- Additional clinical documentation
- Updated medical necessity letter addressing denial reasons
- Peer-reviewed literature supporting treatment
- Any new test results or clinical findings
Note: Many denials are overturned at the internal appeal level when comprehensive clinical evidence is provided.
External Review Through Washington's IRO System
If Cigna upholds the denial after internal appeal, Washington residents can request external review by an Independent Review Organization (IRO).
External Review Process
Eligibility: Available after completing internal appeal or if Cigna misses appeal deadlines
Filing deadline: 180 days from final internal denial
Decision timeline: 30 days for standard review; 72 hours for expedited
Cost: No charge to patient
How to Request External Review
- Submit written request to Cigna within 60 days of final denial
- Include any additional clinical information
- Cigna forwards request to Washington's Office of the Insurance Commissioner
- OIC assigns independent medical reviewers
- IRO makes binding decision on medical necessity
The external review decision is final and binding on Cigna. If the IRO approves coverage, Cigna must provide the medication.
Cost Considerations & Financial Assistance
Vanflyta's high cost ($16,100-$17,900 per month) makes coverage approval crucial for most patients.
Financial Assistance Options
- Daiichi Sankyo Patient Assistance: Contact manufacturer at 1-877-DSI-INFO
- Leukemia & Lymphoma Society: Financial assistance programs for blood cancer patients
- Washington State Pharmaceutical Assistance: Programs for eligible residents
Specialty Pharmacy Coordination
Cigna typically requires Vanflyta to be dispensed through Express Scripts/Accredo specialty pharmacy. Coordinate with your oncologist to ensure proper specialty pharmacy enrollment and prior authorization submission.
When dealing with complex insurance requirements, Counterforce Health helps streamline the process by creating comprehensive prior authorization packets that address payer-specific criteria and reduce delays in medication access.
When to Contact Washington Regulators
Office of the Insurance Commissioner
Phone: 1-800-562-6900 (8:00 AM - 5:00 PM PT, Monday-Friday)
When to contact:
- Cigna doesn't respond within required timeframes
- You need help navigating the appeals process
- You believe your denial was inappropriate
- Post-IRO complaint filing
What to Include in Complaints
- Your contact information and policy details
- Cigna policy/claim numbers
- Complete problem description
- Supporting documentation (denials, appeals, medical records)
- Desired resolution
Frequently Asked Questions
How long does Cigna prior authorization take for Vanflyta in Washington?
Standard PA requests take 5-7 business days. Expedited reviews (for urgent cases) are completed within 24-72 hours.
What if Vanflyta is non-formulary on my Cigna plan?
You can request a formulary exception with clinical documentation showing medical necessity and lack of suitable alternatives.
Can I request expedited appeal if my condition is urgent?
Yes, Washington allows expedited appeals when delays could seriously jeopardize your health or ability to regain maximum function.
Does step therapy apply to FLT3 inhibitors like Vanflyta?
Current Cigna policies don't explicitly require step therapy through other FLT3 inhibitors before approving Vanflyta, though clinical documentation of prior therapy attempts strengthens your case.
What happens if my external review is denied?
You can file a complaint with the Washington Office of the Insurance Commissioner, though the IRO decision is typically final for coverage determinations.
Are there alternatives if Vanflyta isn't covered?
Other FLT3 inhibitors include midostaurin (Rydapt) for newly diagnosed cases and gilteritinib (Xospata) for relapsed/refractory AML.
Sources & Further Reading
- Cigna Quizartinib Coverage Policy
- FDA Vanflyta Prescribing Information
- VANFLYTA REMS Program
- Washington Insurance Appeals Guide
- Washington Office of Insurance Commissioner
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider regarding treatment decisions. Insurance coverage policies may vary by plan and change over time. Verify current requirements with your insurer and healthcare team.
Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.